Novartis revealed new long-term results from the ongoing NEPTUNUS extension study evaluating ianalumab in Sjögren's disease at the American College of Rheumatology Convergence 2026. The findings indicated that reductions in systemic disease activity continued to deepen from Week 48 through Week 108 among participants who maintained continuous monthly doses of 300 mg of ianalumab, as measured by the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI).
Furthermore, improvements remained sustained across both physician- and patient-reported outcomes, as well as salivary flow parameters. The study also recorded efficacy improvements after patients transitioned from placebo over to ianalumab. Across both treatment arms through Week 204, adverse event and serious adverse event rates stayed comparable, bringing no novel safety discoveries.
Thomas Dörner from the Department of Medicine and Clinical Immunology at Charité – Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum Berlin, ein Leibniz-Institut, emphasized the chronic and systemic nature of Sjögren's disease and the necessity of treatment options that offer sustained disease control over extended periods, noting that the findings yield important new insights into long-term treatment responses.
Detailed findings at Week 108 demonstrated that ESSDAI reductions continued to deepen alongside longer treatment durations, displaying a mean reduction from core-study baseline of 7.5 points within the group maintaining continuous monthly ianalumab and 6.5 points within the group switching from placebo to monthly ianalumab at Week 60. Low disease activity rates climbed from 57.1% to 65.1% in the continuous monthly group between Weeks 48 and 108. Meanwhile, patients transitioning from placebo to monthly ianalumab at Week 60 experienced an increase in low disease activity rates from 50.4% to 60.9%.
For patients showing stimulated salivary flow greater than 0.4 mL/min at baseline, improvements were maintained through Week 96 for the continuous monthly group and observed after switching from placebo at Week 60. Improvements in both physician- and patient-reported metrics and symptoms were sustained through Week 108 for continuous monthly users—evaluated by ESSPRI and SSSD—and similarly noted following the placebo switch at Week 60.
Sjögren's disease is classified as a severe systemic autoimmune condition wherein B-cell dysfunction contributes heavily to inflammation, tissue damage, and symptoms like dryness, fatigue, pain, and organ involvement that affect daily life. Angelika Jahreis, Global Head of Development, Immunology at Novartis, highlighted the dual mechanism of ianalumab designed to target this underlying B-cell dysfunction and reinforced the company's commitment to advancing targeted care options.
Regulatory authorities in multiple countries are currently reviewing ianalumab, with an anticipated decision from the US Food and Drug Administration expected during the year 2026. The pivotal global Phase III trials, designated NEPTUNUS-1 and NEPTUNUS-2, previously marked the first global Phase III trials showing statistically significant reductions in disease activity for Sjögren's disease. The NEPTUNUS extension study continues to evaluate the long-term efficacy, safety, and tolerability profile of ianalumab, which is a fully human monoclonal antibody engineered with a dual mechanism of action that depletes B cells and inhibits survival and activation through BAFF-R blockade.
Beyond Sjögren's disease, Novartis is investigating ianalumab for other B-cell driven conditions, including immune thrombocytopenia, systemic lupus erythematosus, lupus nephritis, and systemic sclerosis.
